Business
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds
PHOENIX, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (Nasdaq: CELZ) (the “Company”), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today announced that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants to purchase up to an aggregate of 1,116,136 shares of common stock of the Company originally issued in March 2025, at their current exercise price of $3.7
About this update from Creative Medical Technology Holdings, Inc.
[{"type":"image","alt":"Creative Medical Technology Holdings, Inc.","displaySize":"","headline":null,"caption":"Creative Medical Technology Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":43,"url":"https://media.zenfs.com/en/globenewswire.com/4f20fc41994fc07ca8de61005b80d4fe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GXuNPn9qVk4jpjMkZ_nOOA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/4f20fc41994fc07ca8de61005b80d4fe","width":300,"height":43}},"lazy":false},{"type":"text","content":"PHOENIX, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (Nasdaq: CELZ) (the “Company”), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today announced that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants to purchase up to an aggregate of 1,116,136 shares of common stock of the Company originally issued in March 2025, at their current exercise price of $3.75 per share. The shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-3 (File No. 333-286346). The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $4.2 million, before deducting financial advisory fees.","length":848,"tagName":"p"},{"type":"text","content":"Roth Capital Partners is acting as the Company’s financial advisor for this transaction.","length":88,"tagName":"p"},{"type":"text","content":"In consideration for the immediate exercise of the existing warrants for cash, the Company will issue new unregistered warrants to purchase shares of common stock. The new warrants will be exercisable for an aggregate of up to 2,790,340 shares of common stock, at an exercise price of $3.75 per share, subject to the reduction of such exercise price to the lowest “VWAP” of the Company’s common stock on any trading day during the five trading day period following the issuance date of the new warrants. The new warrants will be exercisable for a period of five years following shareholder approval of the exercise of the warrants. As part of the transaction, the Company also agreed to reduce the exercise price of certain warrants issued in May 20...
More updates from Creative Medical Technology Holdings, Inc.